Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas

Li, C.; Shintani, Satoru; Terakado, Nagaaki; Kłosek, Sebastian; Ishikawa, Tohru; Nakashiro, Koh‐ichi; Hamakawa, Hiroyuki

doi:10.1016/j.ijom.2004.10.016

Cited by 74 publications

(71 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been obtained in previous studies where the tumor microvessel area was found to be higher in tumors than in normal mucosa (20). Comparison of the mean area using the Bonferroni multiple comparison test showed significant differences between the AOSMF and WDSCC groups, but not among any of the other groups.…”

Section: Discussionsupporting

confidence: 90%

Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma

Murgod

Kale²,

Angadi³

et al. 2014

J Oral Sci

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma

Murgod

Kale²,

Angadi³

et al. 2014

J Oral Sci

View full text Add to dashboard Cite

“…Our findings, increased number of vessels (Table 4), coinciding with other reports [31] where vascularization increased between oral lesions presenting with hyperplasia, OED and OSCC. From this it could be inferred that there is a change in the phenotype of OSCC in relation to OED and NOM and strong presence and action of proangiogenic factors on normal endothelial receptors or the presence of numerous mutated endothelial receptors that promote neovascularization in OSCC.…”

Section: Comparing the Immuno-expression Of Endothelial Markers In Nosupporting

confidence: 92%

Comparing the Immuno-Expression of Endothelial Markers in Normal Oral Mucosa, Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma: Relationship between E-Cadherin, Vimentin, CD31, CD117 and Epithelial-Mesenchymal Transition

Alej

Fernández

Marshall

et al. 2017

MOJAP

View full text Add to dashboard Cite

Objective: To evaluate the expression of E-cadherin, Vimentin, CD31, CD117 in Oral Epithelial Dysplasia (OED) and Oral Squamous Cell Carcinoma (OSCC), in comparison with Normal Oral Mucosa (NOM). Material and Methods:Descriptive case study. Histological samples were analyzed by immunohistochemistry against E-cadherin, Vimentin, CD31, CD117. E-cadherin expression was evaluated by extent and intensity, Vimentin was evaluated by intensity and CD31 and C117 quantitatively. Results:The extent of E-cadherin was greater than 75% in all NOM samples, 81% of the OED samples and 47% of the OSCC samples. The intensity of E-cadherin was high in NOM (100%) and in OSCC (36%). Mean CD31 was 21.2 ± 5 in NOM samples, 23.4 ± 5.8 in OED samples and 36.7 ± 10.8 in OSCC samples. Mean CD117 was 7.2 ± 2.5 in NOM samples, 12.8 ± 5.3 in OED samples and 22.7 ± 5.3 in OSCC samples. Conclusion:The molecular marker E-cadherin is significantly more downregulated in dysplastic cells in comparison to NOM cells, while the mesenchymal marker Vimentin is expressed by epithelial cells in samples of NOM, OED and OSCC; questioning their value as prognostic markers. Finally, the quantification of CD31 and CD117 increased significantly in OSCC samples.

show abstract

“…Furthermore, EMD directly enhances the chemotaxis and angiogenesis of endothelial cells in vivo. VEGF induces endothelial proliferation, migration, and specialization in new and developing vascular beds (104). It is also a very potent promoter of neoangiogenesis in many types of tumor (105).…”

Section: Discussionmentioning

confidence: 99%

Emdogain® in carcinogenesis: a systematic review of in vitro studies

2010

View full text Add to dashboard Cite

Emdogain is a commercial product of unknown composition and is clinically used to induce periodontal regeneration. This study aims to review current knowledge of the in vitro effects of Emdogain on oral tissues and, in particular, factors related to carcinoma. A systematic approach was used to review studies from the Embase and Pubmed databases; a total of 76 studies were included. These comprised in vitro studies of the cytokines in, or regulated by, Emdogain and assays designed to study the effects of EMD on human cells in oral tissues or malignant cells. Several studies have shown that EMD regulates the proliferation, migration, adhesion, gene expression, and cytokine production of (pre-)osteoblasts, periodontal fibroblasts, and gingival fibroblasts. However, the effects of EMD on malignant oral cells are not well understood. EMD seems to have broad regulatory effects on malignant cells and on several carcinoma-related factors. Evidence suggests that patients with premalignant or malignant mucosal lesions should not be treated with EMD. (J Oral Sci 52, 1-11, 2010)

show abstract

Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas

Cited by 74 publications

References 18 publications

Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma

Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma

Comparing the Immuno-Expression of Endothelial Markers in Normal Oral Mucosa, Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma: Relationship between E-Cadherin, Vimentin, CD31, CD117 and Epithelial-Mesenchymal Transition

Emdogain® in carcinogenesis: a systematic review of in vitro studies

Contact Info

Product

Resources

About